Research Article Details
| Article ID: | A06822 |
| PMID: | 32734012 |
| Source: | Porto Biomed J |
| Title: | An albino mouse model of nonalcoholic fatty liver disease induced using high-fat liquid "Lieber-DeCarli" diet: a preliminary investigation. |
| Abstract: | Background: Experimental diet models have proven to be vital to understanding the pathophysiology and management of nonalcoholic fatty liver disease (NAFLD). Lieber-DeCarli high-fat, liquid diet have been used to produce NAFLD in rat models. There is, however, currently no information on the effects of this diet in the mouse model. Methods: Ten (n = 10) male albino mice (27.7 ± 2.0 g) were divided into 2 diet groups (n = 5/group). Animals from group 1 were fed with standard chow diet (CD group) and those from group 2 were fed with Lieber-DeCarli high-fat, liquid diet (high-fat diet or HFD group) ad libitum for a period of 4 weeks. Results: Data obtained show insulin resistance in the HFD group with a significant increase in plasma lipid profile. Level of cholesterol and triglycerides in the liver and plasma increased significantly (P < .05) in the HFD group compared with the CD group. Plasma level of tumor necrosis factor alpha increased significantly in the HFD group compared to control. Also, indicators of oxidative stress (malondialdehyde and protein carbonyls) increased significantly coupled with a significant reduction in reduced glutathione (GSH) level and activity of glutathione peroxidase in the liver of mice in the HFD group compared to CD group. Histopathological evaluation of liver sections reveals steatosis with ballooned hepatocytes. Conclusions: Data from the present study suggest that the Lieber-DeCarli high-fat, liquid diet may be vital in the study of fatty liver disease in albino mouse. This model may also produce the features of NAFLD in a shorter time in albino mice. |
| DOI: | 10.1097/j.pbj.0000000000000071 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S04 | Anti-oxidative stress | oxidative stress | α-tocopherol: antioxidant | Vitamin E | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D158 | Glutathione | Chemical drug | DB00143 | MGST3; HPGDS; GSTM2; GSTM5; GPX7 cofactor; MGST2; GSS; GSTM1; GSTK1; GSTM3; GSTM4; GPX1 cofactor; GPX2 cofactor; GPX3 cofactor | -- | Under clinical trials | Details |